# The Cooper Companies, Inc. (COO) Stock Analysis: Healthcare Giant with 14.51% Potential Upside

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-healthcare-giant-with-14-51-potential-upside/4121261409
- Published: 2026-08-31T10:23:21+01:00
- Author: Madison Wilson

Investors keeping a keen eye on the healthcare sector may find The Cooper Companies,
Inc. (NYSE: COO) an intriguing proposition. With a rich history dating back to 1958,
this medical instruments and supplies heavyweight, headquartered in San Ramon, California,
continues to make significant strides in the healthcare industry. The company operates
primarily through two segments: CooperVision, which specializes in cutting-edge 
contact lenses, and CooperSurgical, which focuses on women’s health and fertility
products.

The company’s current market capitalization stands at $13.88 billion, reflecting
its substantial presence in the industry. At a current price of $71.17, with a negligible
price change of 0.21 (0.00%), the stock sits below its 52-week high of $84.32, offering
potential room for growth. The 52-week range of $58.98 to $84.32 showcases the stock’s
recent volatility, a factor prudent investors should consider when weighing investment
decisions.

Analysts have set a target price range of $66.00 to $92.00 for Cooper Companies,
with an average target of $81.50. This translates to a potential upside of 14.51%,
an attractive prospect for investors seeking to capitalize on the company’s future
growth trajectory. Notably, the analyst consensus is optimistic, with 10 buy ratings
and 6 hold ratings, underscoring a positive sentiment in the market.

From a valuation perspective, the lack of a trailing P/E ratio and PEG ratio might
raise questions. However, the forward P/E of 14.25 suggests a reasonable valuation
relative to future earnings projections. This forward-looking metric, combined with
a solid revenue growth rate of 7.90%, indicates that Cooper Companies is on a growth
path, leveraging its innovative product offerings in both the contact lens and women’s
health markets.

In terms of financial performance, the company’s EPS stands at 1.18, and its return
on equity is 2.85%. While these figures might seem modest, they are complemented
by a robust free cash flow of $424.28 million, providing the company with the financial
flexibility to invest in growth opportunities and navigate market uncertainties.

Cooper Companies does not currently offer a dividend, with a payout ratio of 0.00%.
While this may deter income-focused investors, it also suggests that the company
is potentially reinvesting earnings into further expansion and innovation within
its segments.

Technical indicators provide further insights into the stock’s current standing.
The 50-day and 200-day moving averages are at 72.40 and 73.43, respectively, pointing
to a stock that is trading slightly below its recent trends. The Relative Strength
Index (RSI) of 59.85 indicates that the stock is neither overbought nor oversold,
while the MACD and Signal Line values suggest a neutral momentum.

Overall, The Cooper Companies offers a compelling investment case for those interested
in the healthcare sector, driven by its dual-segment strategy and significant market
presence. As the company continues to innovate and expand its product offerings,
particularly in the burgeoning fields of contact lenses and women’s health, it presents
a potentially attractive opportunity for investors looking to capitalize on its 
growth potential and the favorable analyst outlook.

Share on:
